News
SGP
24.89
+0.16%
0.04
Weekly Report: what happened at SGP last week (0803-0807)?
Weekly Report · 2d ago
SpyGlass Pharma: Buy Rating Reiterated as Late-Stage Glaucoma Pipeline Advances; $37 Price Target Maintained
TipRanks · 4d ago
SpyGlass Pharma Q2 GAAP EPS of -$0.59
Seeking Alpha · 5d ago
SpyGlass Pharma reports Q2 EPS (59c), consensus (55c)
TipRanks · 5d ago
SpyGlass Pharma, Inc. Loss At -$19.864 Mln In Q2
NASDAQ · 5d ago
Press Release: SpyGlass Pharma Reports Second -2-
Dow Jones · 5d ago
SpyGlass Pharma Insiders Enjoying US$1.1m Appreciation On US$2.16m Investment
Simply Wall St · 08/05 11:09
Weekly Report: what happened at SGP last week (0727-0731)?
Weekly Report · 08/03 10:32
Weekly Report: what happened at SGP last week (0720-0724)?
Weekly Report · 07/27 10:37
Weekly Report: what happened at SGP last week (0713-0717)?
Weekly Report · 07/20 10:33
Weekly Report: what happened at SGP last week (0706-0710)?
Weekly Report · 07/13 10:35
Weekly Report: what happened at SGP last week (0629-0703)?
Weekly Report · 07/06 10:40
Weekly Report: what happened at SGP last week (0622-0626)?
Weekly Report · 06/29 10:34
Weekly Report: what happened at SGP last week (0615-0619)?
Weekly Report · 06/22 10:46
Weekly Report: what happened at SGP last week (0608-0612)?
Weekly Report · 06/15 10:46
Weekly Report: what happened at SGP last week (0601-0605)?
Weekly Report · 06/08 10:40
Weekly Report: what happened at SGP last week (0525-0529)?
Weekly Report · 06/01 10:47
Analysts Offer Insights on NA Companies: SpyGlass Pharma (SGP) and Fiserv (FISV)
TipRanks · 05/29 11:40
Weekly Report: what happened at SGP last week (0518-0522)?
Weekly Report · 05/25 10:51
Jefferies Sticks to Its Buy Rating for SpyGlass Pharma (SGP)
TipRanks · 05/19 16:55
More
Webull provides a variety of real-time SGP stock news. You can receive the latest news about SpyGlass Pharma, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SGP
SpyGlass Pharma Inc is a United States-based ophthalmic drug delivery company. The Company is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.